Archimandritis A, Tjivras M, Davaris P, Tryfonos M, Diamantis T, Nikolopoulou V, Katsakoulis E
Department of Pathologic Physiology, University of Athens Medical School, Laikon General Hospital, Greece.
Clin Ther. 1993 Jul-Aug;15(4):657-61.
Fifty-four patients (41 men, 13 women), aged 17 to 78 years (mean +/- SD, 48.13 +/- 13.5 years), with endoscopically confirmed healing of their duodenal ulcer after treatment with sucralfate (2 gm BID for 4 to 8 weeks) were recruited for this study. They were started on a 6-month maintenance treatment with sucralfate 1 gm BID. Endoscopy was done at the end of the 6-month period or whenever there was any evidence of ulcer relapse. Helicobacter pylori antral colonization (CLO test) and antral gastritis were estimated from biopsy samples taken before, and at the end of, the healing treatment, as well as at the end of the maintenance treatment. Cumulative relapse rate after 6 months was 15% (8 of 54). No patient discontinued treatment because of side effects. No influence of sucralfate on H pylori antral colonization or antral gastritis was observed after the healing or maintenance treatment. It is concluded that sucralfate 1 gm BID for 6 months is an effective maintenance treatment for duodenal ulcer, but has no beneficial effect on either H pylori antral colonization or antral gastritis.
本研究招募了54例患者（41例男性，13例女性），年龄在17至78岁之间（平均±标准差，48.13±13.5岁），这些患者在接受硫糖铝治疗（2克，每日两次，持续4至8周）后经内镜确认十二指肠溃疡已愈合。他们开始接受为期6个月的硫糖铝维持治疗，剂量为1克，每日两次。在6个月疗程结束时或出现任何溃疡复发迹象时进行内镜检查。从愈合治疗前、愈合治疗结束时以及维持治疗结束时采集的活检样本中评估幽门螺杆菌胃窦定植情况（CLO试验）和胃窦炎。6个月后的累积复发率为15%（54例中的8例）。没有患者因副作用而停药。在愈合或维持治疗后，未观察到硫糖铝对幽门螺杆菌胃窦定植或胃窦炎有影响。结论是，硫糖铝1克，每日两次，治疗6个月是十二指肠溃疡的有效维持治疗方法，但对幽门螺杆菌胃窦定植或胃窦炎均无有益作用。
